Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ASU scientists develop new, rapid pipeline for antimicrobials

14.12.2017

High-throughput technology can go from idea to discovery to stockpiling 1,000 doses within a week

With hospitals more often reaching for antibiotics of last resort to fight infections and recent Ebola and Zika outbreaks crossing borders like never before, the worldwide scientific community has been challenged with developing new antimicrobials to safeguard the population.


ASU scientists have recently met a challenge of developing a new class of antimicrobials, called synbodies, to safeguard the population against infectious threats -- all within a week.

Credit: Biodesign Institute, Arizona State University

The research arm of the U.S. Department of Defense, the Defense Advanced Research Program Agency, or DARPA, is known for taking on out-sized challenges such as this. And so, they put out a call for researchers to figure out how to make at least 1000 doses to any unknown pathogen - in a week.

An ASU team was one of the few that rose to this challenge.

"As far as we know we were the only team to figure out how to do this for any pathogen - virus or bacterium," said research leader Stephen Albert Johnston, who directs the ASU Biodesign Institute's Center for Innovations in Medicine and is a professor in the School of Life Sciences. "While the system is designed to create antimicrobials in an extreme emergency - which we hope is never needed - the basic elements can be applied to improve conventional approaches to making anti-infectives.

"My research center thrives on taking on projects most think cannot be done. This challenge was too good not to respond."

Synthetic sentinels

Antibodies are large, Y-shaped proteins produced by the human immune system to ward off foreign invaders. Our bodies mount this defense rapidly, especially if they have seen the invader before, producing the needed antibody within days of infection.

But to make them in the lab, antibodies specific for just one invader can take months, and be an expensive proposition.

Johnston wanted to mimic nature's approach while dramatically reducing the antimicrobial discovery and production time.

For the past decade, Johnston's team has been a pioneer in developing lab-made versions that focus on just the business end of antibodies, critical pathogen recognition elements, called synthetic antibodies, or synbodies.

Synbodies are made from two short protein fragments, called peptides, which are joined together to form a small, antibody-like compound still large enough to do its job.

Chipping away

But even the process of making synbodies typically takes several months.

Synbodies are selected on peptide chips containing a premade set of 10,000 peptides placed in neat rows on a microscope glass slide, called a microarray.

To generate a synbody with antibiotic activity, a solution containing bacteria or viruses can be placed on the microarray.

"Our solution to save time was to pre-screen a large number of pathogens on the microarray and find 100 peptides that would be diverse enough so that any pathogen screened would bind to two or more peptides," said Chris Diehnelt, an associate research professor in Johnston's center who oversaw the lab experiments.

They could stockpile large stocks of these 100 peptides in advance so that 1,000 or more doses of a therapeutic could be quickly produced, screening the best candidates that block a given pathogen. These candidates are then produced in large amounts, purified and tested in mice for acute toxicity so that the whole process is completed in a week.

For their proof-of-concept, they screened a total of 21 different viruses and bacteria against their synbody arrays.

"We found that the majority of the peptides recognized one pathogen," said Diehnelt.

In addition, they tested their system against two unknown pathogens that were not used in the study.

"The data showed that this array can potentially identify binding peptides for any given pathogen," said Diehnelt.

A shot in the arm

"With this approach, dozens or even hundreds of synbodies can be produced in a day," said Johnston.

The best candidates are quickly evaluated both for effective killing and toxicity to humans and can be produced on a large scale.

Finally, their system was tested against two societal scourges and major worldwide health concerns: a potentially pandemic flu strain (H1N1 influenza) as a viral test and a bacterium that causes surgery-related infections, S. epidermidis.

"Our data indicate that a new virus or bacterium can be screened against the small peptide library to discover binding peptides that can be converted into neutralizing antiviral and antibacterial synbodies in a rapid manner," said Diehnelt.

The next steps would be to prepare the final product for an IV delivery, and to scale up the system to produce enough product for a population-wide use ----should the next Ebola, Zika or unanticipated outbreak occur.

"One key, unique feature of our synbody technology is that the same platform can produce synbodies with direct antibiotic or antiviral activity, and we can do it at a fraction of the potential cost as current, commercially produced therapeutic antibodies," said Johnston.

This is good news for saving lives before the next inevitable outbreak occurs.

And for Johnston, who has also spun out companies based on other ASU technologies he has developed or co-developed, it could also mean big business in addition to the potential to save lives. The global therapeutic monoclonal antibody market and cancer therapies are in high demand, with an estimated market size close to $100 billion for 2018.

###

This work was funded by a grant from the Defense Advanced Research Projects Agency (W911NF-10-0299) to professor Stephen Albert Johnston under the 7-Day Biodefense Program.

Media Contact

Joseph Caspermeyer
joseph.caspermeyer@asu.edu
480-258-8972

 @ASU

http://asunews.asu.edu/ 

Joseph Caspermeyer | EurekAlert!

Further reports about: antibiotic bacteria bacterium pathogens peptides therapeutic

More articles from Health and Medicine:

nachricht Building blocks for new medications: the University of Graz is seeking a technology partner
19.03.2019 | Karl-Franzens-Universität Graz

nachricht Scientists find new approach that shows promise for treating cystic fibrosis
14.03.2019 | NIH/National Heart, Lung and Blood Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Stellar cartography

The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.

A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...

Im Focus: Heading towards a tsunami of light

Researchers at Chalmers University of Technology and the University of Gothenburg, Sweden, have proposed a way to create a completely new source of radiation. Ultra-intense light pulses consist of the motion of a single wave and can be described as a tsunami of light. The strong wave can be used to study interactions between matter and light in a unique way. Their research is now published in the scientific journal Physical Review Letters.

"This source of radiation lets us look at reality through a new angle - it is like twisting a mirror and discovering something completely different," says...

Im Focus: Revealing the secret of the vacuum for the first time

New research group at the University of Jena combines theory and experiment to demonstrate for the first time certain physical processes in a quantum vacuum

For most people, a vacuum is an empty space. Quantum physics, on the other hand, assumes that even in this lowest-energy state, particles and antiparticles...

Im Focus: Sussex scientists one step closer to a clock that could replace GPS and Galileo

Physicists in the EPic Lab at University of Sussex make crucial development in global race to develop a portable atomic clock

Scientists in the Emergent Photonics Lab (EPic Lab) at the University of Sussex have made a breakthrough to a crucial element of an atomic clock - devices...

Im Focus: Sensing shakes

A new way to sense earthquakes could help improve early warning systems

Every year earthquakes worldwide claim hundreds or even thousands of lives. Forewarning allows people to head for safety and a matter of seconds could spell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International Modelica Conference with 330 visitors from 21 countries at OTH Regensburg

11.03.2019 | Event News

Selection Completed: 580 Young Scientists from 88 Countries at the Lindau Nobel Laureate Meeting

01.03.2019 | Event News

LightMAT 2019 – 3rd International Conference on Light Materials – Science and Technology

28.02.2019 | Event News

 
Latest News

Levitating objects with light

19.03.2019 | Physics and Astronomy

New technique for in-cell distance determination

19.03.2019 | Life Sciences

Stellar cartography

19.03.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>